Jacob van Naarden, Chief Business Officer at Loxo Oncology, Inc. (LOXO), sold 9,000 shares at $130.59 ($1.2M) on 2018-12-10, disclosed to the SEC on 2018-12-12.
Open-market sale of $1.2M LOXO by Chief Business Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $130.59 | 400 | $52K | 4.3% |
| 2 | $132.23 | 1,000 | $132K | 10.8% |
| 3 | $133.17 | 900 | $120K | 9.8% |
| 4 | $134.65 | 1,400 | $189K | 15.5% |
| 5 | $135.14 | 500 | $68K | 5.5% |
| 6 | $136.48 | 200 |
| $27K |
| 2.2% |
| 7 | $137.39 | 100 | $14K | 1.1% |
| 8 | $134.74 | 400 | $54K | 4.4% |
| 9 | $135.92 | 800 | $109K | 8.9% |
| 10 | $137.09 | 1,759 | $241K | 19.8% |
| 11 | $137.73 | 500 | $69K | 5.6% |
| 12 | $139.23 | 500 | $70K | 5.7% |
| 13 | $140.16 | 541 | $76K | 6.2% |
| Total | $135.50 avg | 9,000 | $1.2M | 100% |
| Filing → |
| LOXO | SELL | 2018-10-05 | $2.0M | — | Filing → |
| LOXO | SELL | 2018-09-14 | $2.8M | — | Filing → |
| LOXO | SELL | 2018-08-15 | $2.9M | — | Filing → |